Pharmanutra

Regulatory Filings • Apr 7, 2021

Informazione Regolamentata n. 20106-18-2021		Data/Ora Ricezione 07 Aprile 2021 08:52:24	MTA - Star
Societa'	:	Pharmanutra S.p.A.
Identificativo Informazione Regolamentata	:	144921
Nome utilizzatore	:		PHARMANUTRAN02 - Lacorte Roberto
Tipologia	:	REGEM
Data/Ora Ricezione	:	07 Aprile 2021 08:52:24
Data/Ora Inizio Diffusione presunta	:	07 Aprile 2021 08:52:26
Oggetto	:	PR - PHARMANUTRA SPA new study on Apportal
Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A.: ANEW STUDY DEMONSTRATES THE EFFECTS OF USING APPORTAL® IN PATIENTS SUFFERING FROM CHRONIC COVID SYNDROME

Pisa, 7 th April 2021 – PharmaNutra S.p.A. (MTA; Ticker PHN), specialised in iron-based nutritional supplements and medical devices for muscles and joints, communicates the publication of a new, important scientific study on the treatment of post Covid-19 chronic fatigue with ApportAL® .

ApportAL® is a food supplement, launched on the market by PharmaNutra S.p.A. in 2018, containing 19 nutrients, including vitamins, amino acids, plant extracts and minerals in Sucrosomial® form, a patented technology that guarantees greater stability and tolerability and promotes mineral absorption. ApportAL® is already widely used where support for normal immune function is needed, such as conditions of fatigue and tiredness, or to help the energy metabolism during sports, postoperative physiological recovery or in the winter.

This study was conducted with the help of general practitioners throughout Italy and included around 200 post-Covid patients suffering from persistent fatigue. The patients involved were advised to take ApportAL® for 28 consecutive days, while their levels of fatigue and quality of life were monitored after 14 and after 28 days.

The preliminary results show that taking ApportAL® helps to reduce the sensation of persistent fatigue and improve quality of life. Particularly, for the first 100 patients, the data collected indicate that 95% of them obtained a significant benefit over 28 days of taking the supplements. Furthermore, particularly rapid recovery was found in patients who had indicated a more severe level of initial fatigue, including women and the over-60s.

This study may be the first to offer a valid remedy and targeted nutritional approach, thanks to the action and synergies of the components of a supplement like ApportAL® , promoting recovery from post-Covid-19 chronic fatigue.

"The results of the investigation conducted on post-Covid patients are extremely significant. First of all because chronic fatigue following infection is unfortunately a very serious and widespread problem, and secondly because it is the world's first study to analyse the effect of a nutritional supplement in this context," explains Andrea

Lacorte, President of PharmaNutra S.p.A.. "We are aware of the properties and benefits of ApportAL® but having the certainty that it can help post-Covid recovery means offering a real contribution to the health emergency and to those who are having to cope with a particularly difficult and delicate phase today. PharmaNutra's work focuses specifically on this principle: striving to build a future where scientific progress is at the service of collective well-being, understood as prevention and attention to health."

This investigation is in fact only the latest in a series of over 140 publications on clinical trials and basic research conducted by PharmaNutra. The scientific proof collected over the years and the continuous investments in Research and Development have helped the companies in the Group to acquire unique technical and scientific know-how, recognised by 17 patents and developing 17 raw materials, controlled throughout the whole value chain and held exclusively on both the Italian and foreign markets.

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative medical devices, handling the entire production process, from proprietary raw materials to the finished product. The effectiveness of its products is documented by considerable scientific proof, including 112 publications. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 39 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence. PharmaNutra.it

For further information:

Via Delle Lenze, 216/b - 56122 Pisa Tel. +39 050 7846500 investorrelation@PharmaNutra.it

Internal Press Office press@calabughi.com

PharmaNutra S.p.A. Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan Tel. +39 02 83635708

Matteo Russo mrusso@sprianocommunication.com Cristina Tronconi ctronconi@sprianocommunication.com